Back to Research Hub
Collegium Pharmaceutical, Inc.
COLL
$34.40+1.13 (+3.40%)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations…
StreetsValue research for Collegium Pharmaceutical, Inc. (COLL)
Members get the full report for Collegium Pharmaceutical, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.